母胎医学会咨询系列#53:妊娠期肝内胆汁淤积症(替代2011年4月咨询#13)
妊娠期肝内胆汁淤积症以瘙痒和血清胆汁酸升高为特征,对孕妇风险小但对胎儿有早产、胎粪污染羊水和死胎等显著风险。本咨询基于现有证据提出7条推荐,涵盖胆汁酸和转氨酶检测、熊去氧胆酸治疗、产前胎儿监测、分娩时机、产前皮质类固醇使用及无实验室证实者避免早产。
要点
- 疑似ICP应检测血清胆汁酸和肝转氨酶水平(GRADE 1B)。
- 熊去氧胆酸为 maternal 症状一线治疗(GRADE 1A)。
- 总胆汁酸≥100 μmol/L者建议36 0/7周分娩,<100 μmol/L者36 0/7至39 0/7周分娩。
核心结论
- ICP对孕妇风险小但显著增加胎儿早产、胎粪污染羊水和死胎风险。
- 基于证据提出7条推荐,涉及检测、治疗、监测和分娩时机。
研究设计与样本
- 制定机构:母胎医学会(Society for Maternal-Fetal Medicine)。
- 方法:综述当前ICP文献并提供基于证据的推荐,采用GRADE分级。
主要发现
- ICP以瘙痒和血清胆汁酸升高为特征,对胎儿有显著风险包括早产、胎粪污染羊水和死胎。
关键数值与推荐
- 推荐疑似ICP患者检测血清胆汁酸和肝转氨酶水平(GRADE 1B)。
- 推荐熊去氧胆酸作为 maternal 症状一线治疗(GRADE 1A)。
- 建议确诊ICP患者开始产前胎儿监测,时机为异常胎儿检测结果会触发分娩的孕周或诊断时(若诊断较晚)(GRADE 2C)。
- 推荐总胆汁酸≥100 μmol/L者36 0/7周分娩,因死胎风险在该孕周前后显著增加(GRADE 1B)。
- 推荐总胆汁酸<100 μmol/L者36 0/7至39 0/7周分娩(GRADE 1C)。
临床怎么用
- 对疑似ICP孕妇检测血清胆汁酸和肝转氨酶。
- 确诊后使用熊去氧胆酸缓解 maternal 症状。
- 根据总胆汁酸水平决定分娩时机:≥100 μmol/L者36 0/7周,<100 μmol/L者36 0/7至39 0/7周。
- <37周分娩者使用产前皮质类固醇促胎肺成熟。
- 无实验室证实胆汁酸升高者避免<37周早产。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intrahepatic cholestasis of pregnancy is a hepatic disorder characterized by pruritus and an elevation in serum bile acid levels. Although intrahepatic cholestasis of pregnancy poses little risk for women, this condition carries a significant risk for the fetus, including complications such as preterm delivery, meconium-stained amniotic fluid, and stillbirth. The purpose of this Consult is to review the current literature on intrahepatic cholestasis of pregnancy and provide recommendations based on the available evidence. The recommendations by the Society for Maternal-Fetal Medicine are as follows: (1) we recommend measurement of serum bile acid and liver transaminase levels in patients with suspected intrahepatic cholestasis of pregnancy (GRADE 1B); (2) we recommend that ursodeoxycholic acid be used as the first-line agent for the treatment of maternal symptoms of intrahepatic cholestasis of pregnancy (GRADE 1A); (3) we suggest that patients with a diagnosis of intrahepatic cholestasis of pregnancy begin antenatal fetal surveillance at a gestational age when delivery would be performed in response to abnormal fetal testing results or at the time of diagnosis if the diagnosis is made later in gestation (GRADE 2C); (4) we recommend that patients with total bile acid levels of ≥100 μmol/L be offered delivery at 36 0/7 weeks of gestation, given that the risk of stillbirth increases substantially around this gestational age (GRADE 1B); (5) we recommend delivery between 36 0/7 and 39 0/7 weeks of gestation for patients with intrahepatic cholestasis of pregnancy and total bile acid levels of <100 μmol/L (GRADE 1C); (6) we recommend administration of antenatal corticosteroids for fetal lung maturity for patients delivering before 37 0/7 weeks of gestation if not previously administered (GRADE 1A); (7) we recommend against preterm delivery at <37 weeks of gestation in patients with a clinical diagnosis of intrahepatic cholestasis of pregnancy without laboratory confirmation of elevated bile acid levels (GRADE 1B).
引用
- Lee RH, Mara Greenberg, Metz TD, et al. Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy: Replaces Consult #13, April 2011. Am J Obstet Gynecol. 2020. PMID: 33197417. doi:10.1016/j.ajog.2020.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。